Bill Alpert
Senior Writer at Barron's
Bill Alpert is a Senior Writer at Barron’s, where since 1984 he has published nerdy feature stories, columns and investigative projects of use to investors.
Articles
-
3 weeks ago |
barrons.com | Bill Alpert
The legal barriers that keep everyday investors from pursuing alternative assets—or the other way around—should fall over the next year. The White House, Congress and federal agencies each seem willing to clear their stretch of the track.
-
3 weeks ago |
barrons.com | Bill Alpert
-
3 weeks ago |
barrons.com | Bill Alpert
The U.S. Securities and Exchange Commission’s new boss, Paul Atkins, presented his agency’s budget request to the Senate—a document that shows deep cuts to the enforcement staff.
-
3 weeks ago |
barrons.com | Bill Alpert
Biotech firm Kymera Therapeutics announced strong results Monday, in the first human tests of a pill for autoimmune ailments like dermatitis and asthma. Its drug seems about a year ahead of other firms developing pills in the hot class of drugs called “protein degraders”, which can block the on-switch for troublesome genes.
-
4 weeks ago |
barrons.com | Bill Alpert
After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly , another class of weight-loss drugs called amylins is drawing the drug industry’s attention and dollars.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 941
- DMs Open
- Yes
What happens when a private club admits everybody ? Congress Will Open Private Markets to Everyone, Next Year https://t.co/8uFz0S8oyp via @BarronsOnline
Unilateral Disarmament at the SEC. The SEC Costs Taxpayers Nothing. It Is Cutting 17% of Its Staff https://t.co/dgiwc1qM2v via @BarronsOnline
Amylin drugs from $LLY, $NVO, $ZEAL, and $MTSR are not less-filling. Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin. https://t.co/ajmCvJsoD7 via @BarronsOnline